Cargando…
Src inhibitors act through different mechanisms in Non-Small Cell Lung Cancer models depending on EGFR and RAS mutational status
Resistance to the EGFR tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib, often related to Ras or secondary EGFR mutations, is a relevant clinical issue in Non-Small Cell Lung Cancer (NSCLC). Although Src TK has been involved in such resistance, clinical development of its inhibitors has bee...
Autores principales: | Formisano, Luigi, D'Amato, Valentina, Servetto, Alberto, Brillante, Simona, Raimondo, Lucia, Di Mauro, Concetta, Marciano, Roberta, Orsini, Roberta Clara, Cosconati, Sandro, Randazzo, Antonio, Parsons, Sarah J., Montuori, Nunzia, Veneziani, Bianca Maria, De Placido, Sabino, Rosa, Roberta, Bianco, Roberto |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4694888/ https://www.ncbi.nlm.nih.gov/pubmed/26325669 |
Ejemplares similares
-
Everolimus induces Met inactivation by disrupting the FKBP12/Met complex
por: Raimondo, Lucia, et al.
Publicado: (2016) -
Urokinase-type plasminogen activator receptor (uPAR) expression enhances invasion and metastasis in RAS mutated tumors
por: Mauro, Concetta Di, et al.
Publicado: (2017) -
Epidermal growth factor-receptor activation modulates Src-dependent resistance to lapatinib in breast cancer models
por: Formisano, Luigi, et al.
Publicado: (2014) -
The dual PI3K/mTOR inhibitor PKI-587 enhances sensitivity to cetuximab in EGFR-resistant human head and neck cancer models
por: D'Amato, V, et al.
Publicado: (2014) -
Hedgehog signalling pathway orchestrates angiogenesis in triple-negative breast cancers
por: Di Mauro, Concetta, et al.
Publicado: (2017)